Institution
Roussel Uclaf
About: Roussel Uclaf is a based out in . It is known for research contribution in the topics: Alkyl & Alkoxy group. The organization has 1888 authors who have published 2338 publications receiving 36508 citations.
Topics: Alkyl, Alkoxy group, Aryl, Carbon, Carboxylic acid
Papers published on a yearly basis
Papers
More filters
•
21 Mar 1990TL;DR: In this article, a compound is selected from the group consisting of a compound of the formula ##STR1## wherein R 6 is chosen from a compound consisting of halogen, --CH 3, fluorine and chlorine, R 9 and R 11 together form a second bond at 9(11) or R 9 is hydrogen or fluorine, R 11 is selected by the group consisnting of hydrogen, --OH and ═O, the dotted lines in rings A and B indicate a possible additonal bond at 1(2) and 6(7),
Abstract: A compound selected from the group consisting of a compound of the formula ##STR1## wherein R 6 is selected from the group consisting of halogen, --CH 3 , fluorine and chlorine, R 9 and R 11 together form a second bond at 9(11) or R 9 is hydrogen or fluorine and R 11 is selected from the group consisnting of hydrogen, --OH and ═O, the dotted lines in rings A and B indicate a possible additonal bond at 1(2) and 6(7), R 17 is hydrogen or acyl or an organic carboxylic acid of 1 to 18 carbon atoms, R' 17 is ##STR2## Z is selected from the group consisting of a single bond, alkylene of 1 to 5 carbon atoms and alkenylene and alkynylene of 2 to 5 carbon atoms, P is pyrimidinyl or pyridyl optionally substituted with one or two individual members of the group consisting of --NH 2 , alkylamino, dialkylamino and aminated 5- or 6- membered heterocycles optionally substituted with alkyl of 1 to 3 carbon atoms and its non-toxic, pharmaceutically acceptable acid addition salts having anti-inflammatory and anti-oxidation activity.
25 citations
••
TL;DR: The studies suggest that RU 58668 may be used for the treatment of ER+ patients which are primarily resistant to or which escaped from tamoxifen treatment and its preventive activity on tumor take suggests its use as an adjuvant to prevent the development of metastases.
Abstract: The recently described pure antiestrogen RU 58668 displayed potent antiproliferative activities in vitro on several ER+ human mammary cell lines, stimulated either by estradiol or by endogenous or exogenous growth factors. Moreover, when administered to nude mice it proved to be the only antiestrogen to induce regression (at least 10 weeks) of estradiol-stimulated MCF-7 tumors, whereas tamoxifen only stabilized the tumor volume for 4 to 8 weeks. So the first purpose of this work was to study the effect of RU 58668 for 6 months and to evaluate its activity on tumors which escaped from the tamoxifen treatment. On the other hand, we looked for its effect on models more related to frequently described clinical observations, such as the overexpression of an oncogene or the implication of autocrine or paracrine growth factors. Long-term studies of RU 58668 on the estradiol-stimulated MCF-7 model showed that this compound induced a shrinking of tumor volumes for at least 25 weeks (3 to 6 times longer than the stabilization induced by tamoxifen) and was able to reduce the volume of tumors which escaped from, or even were stimulated by, tamoxifen. On models of spontaneously growing tumors, where the overexpression of an oncogene or the production of growth factors was involved, RU 58668 induced the same tumor shrinking that was previously observed on estradiol- or tamoxifen-stimulated models. Finally, when MCF-7 cells were injected in the uteri, a spontaneous tumor take was observed (in about 80-90% of the animals), leading to a more than twofold increase in uterus weight. This growth is largely stimulated by estradiol and tamoxifen. On this model, histological examination showed that only 30% of the animals receiving RU 58668 displayed tumoral microfoci. These studies suggest that RU 58668 may be used for the treatment of ER+ patients which are primarily resistant to or which escaped from tamoxifen treatment. Its preventive activity on tumor take also suggests its use as an adjuvant to prevent the development of metastases.
25 citations
••
TL;DR: In this paper, a modification of the Corey CBS methodology for the asymmetric reduction of the dienone 3 A affords the Dienol 4 A with an ee = 98% (92% yield).
25 citations
••
TL;DR: This new purification procedure confirms the anti-HIV activity of trichosanthin on some cell lines in different biological assays.
Abstract: Trichosanthin was purified from fresh Chinese root tubers of Trichosanthes kirilowii and evaluated for anti-HIV activity. Trichosanthin inhibited syncytium formation between infected H9 cells and uninfected Sup-T1 cells from 0.5 to 4 micrograms/ml. Trichosanthin also inhibited HIV replication in H9 and CEM-SS cells at 1 microgram/ml, but was toxic for MT-4 cells (HTLV-I-positive), at doses greater than 0.25 microgram/ml. This new purification procedure confirms the anti-HIV activity of trichosanthin on some cell lines in different biological assays.
25 citations
••
TL;DR: A cDNA encoding a chicken angiotensin II receptor from adrenal gland was isolated and revealed pharmacological properties distinct from mammalian receptors and a functional coupling leading to the increase in inositol phosphate production.
25 citations
Authors
Showing all 1888 results
Name | H-index | Papers | Citations |
---|---|---|---|
Fernand Labrie | 110 | 885 | 48308 |
Lionel H. Opie | 84 | 519 | 25964 |
Alain Bélanger | 70 | 244 | 16469 |
Michel J. Tremblay | 53 | 273 | 10485 |
Pierre Monsan | 51 | 216 | 8049 |
Samir Z. Zard | 50 | 575 | 10739 |
Alejandro Aruffo | 47 | 123 | 14084 |
Samuel S.C. Yen | 47 | 96 | 6865 |
Dominique Maraninchi | 47 | 188 | 8108 |
Serge Erlinger | 46 | 152 | 8200 |
Romain Lefebvre | 40 | 221 | 5269 |
William B. Motherwell | 39 | 305 | 6357 |
Jean-Pierre Raynaud | 38 | 104 | 5075 |
André Lemay | 38 | 114 | 4264 |
Patrick J. Creaven | 32 | 102 | 3435 |